Skip to main content

3 Result(s)

within P. A. Thompson Remove this filter Medicine & Public Health Remove this filter Hematology Remove this filter

and

  1. No Access

    Article

    Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway

    Ibrutinib, a covalent inhibitor of Bruton Tyrosine Kinase (BTK), is approved for treatment of patients with relapsed/refractory or treatment-naïve chronic lymphocytic leukemia (CLL). Besides directly inhibitin...

    K Kondo, H Shaim, P A Thompson, J A Burger, M Keating, Z Estrov, D Harris… in Leukemia (2018)

  2. No Access

    Article

    Umbilical cord blood graft engineering: challenges and opportunities

    We are entering a very exciting era in umbilical cord blood transplantation (UCBT), where many of the associated formidable challenges may become treatable by ex vivo graft manipulation and/or adoptive immunother...

    P A Thompson, K Rezvani, C M Hosing, B Oran, A L Olson… in Bone Marrow Transplantation (2015)

  3. No Access

    Article

    Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma

    P A Thompson, H M Prince, J F Seymour, D Ritchie, K Stokes… in Bone Marrow Transplantation (2011)